Hyderabad, India, July 27, 2011  

Dr. Reddy’s announces the launch of Gemcitabine for Injection

Hyderabad, India, July 27, 2011: Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar®* in the US market on July 25, 2011, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Gemcitabine for injection.

The Gemzar® brand had U.S. sales of approximately $ 634 million for the most recent twelve months ending May 31, 2011 according to IMS Health.

Dr. Reddy’s Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

*Gemzar® is a registered trademark of Eli Lilly and Company.
IMS National Sales Perspectives: Retail and Non-Retail MAT MAY 2011

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at / +91-40-66834297
Raghavender R at / +91-40-49002135
Milan Kalawadia (USA) at / +1 908-203-4931

S Rajan at / +91-40- 49002445